DPP4 and metabolic dysfunction-associated steatotic liver disease: The results of the present study, together with those of previous reports [19,21,22], have prompted us to conduct a clinical trial to determine the effectiveness of DPP-4 inhibitors for the prevention and treatment of NAFLD.